MapLight Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-161.2M | $-77.6M |
| Depreciation & Amortization | — | — |
| Depreciation | $578.0K | $701.0K |
| Amortization | — | — |
| Stock-Based Compensation | $36.0M | $1.1M |
| Net Cash from Operating Activities | $-138.1M | $-78.8M |
| Investing Activities | ||
| Capital Expenditures | $473.0K | $770.0K |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-323.2M | $-80.8M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $469.8M | $118.1M |
| Net Change in Cash | — | — |
| Free Cash Flow | $-138.6M | $-79.6M |